Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ixmyelocel-T

Cell therapy · developed by Vericel

Phase 3 Most advanced trial (none active)
VCEL Developer
1 Registered trials

What is Ixmyelocel-T?

Ixmyelocel-T is a cell therapy given as intramuscular injections into the affected leg. It is being studied in critical limb ischemia, a severe circulatory condition of the legs.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Therapy area
Cardiovascular
Developer
Vericel Corporation (VCEL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01483898 Phase 3 Critical Limb Ischemia Completed VCEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Critical Limb Ischemia

More from Vericel

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VCEL page.

Follow VCEL, the company behind Ixmyelocel-T

See VCEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VCEL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.